Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INONASDAQ:LNSRNASDAQ:SKINNASDAQ:TLSI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINOInovio Pharmaceuticals$2.10+1.7%$1.96$1.42▼$12.33$76.46M1.34628,321 shs114,437 shsLNSRLENSAR$12.55+0.4%$13.50$3.50▼$17.31$147.79M0.5284,419 shs28,145 shsSKINBeauty Health$1.88-2.3%$1.42$0.78▼$2.24$234.98M1.16963,311 shs125,192 shsTLSITriSalus Life Sciences$5.11-2.4%$5.38$3.50▼$6.04$194.68M0.4743,722 shs4,634 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINOInovio Pharmaceuticals+6.74%+8.42%+4.57%+17.71%-74.12%LNSRLENSAR+2.04%+1.63%-7.89%-11.67%+195.97%SKINBeauty Health-0.52%+25.49%+19.25%+43.28%+6.67%TLSITriSalus Life Sciences-1.13%+0.77%-5.94%-6.27%-10.14%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINOInovio Pharmaceuticals3.7807 of 5 stars3.32.00.04.33.20.00.6LNSRLENSAR0.8592 of 5 stars2.03.00.00.00.02.50.0SKINBeauty Health0.4091 of 5 stars0.80.00.00.02.73.30.0TLSITriSalus Life Sciences3.0965 of 5 stars3.65.00.00.00.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINOInovio Pharmaceuticals 2.50Moderate Buy$9.75365.39% UpsideLNSRLENSAR 2.00Hold$15.0019.57% UpsideSKINBeauty Health 1.67Reduce$1.42-24.44% DownsideTLSITriSalus Life Sciences 3.25Buy$10.75110.58% UpsideCurrent Analyst Ratings BreakdownLatest INO, TLSI, SKIN, and LNSR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025INOInovio PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Perform ➝ Sector Perform$5.00 ➝ $5.005/14/2025INOInovio PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$15.00 ➝ $13.005/5/2025SKINBeauty HealthCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$1.50 ➝ $1.253/28/2025TLSITriSalus Life SciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.00(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINOInovio Pharmaceuticals$220K349.20N/AN/A$1.90 per share1.10LNSRLENSAR$53.49M2.77N/AN/A$0.42 per share29.87SKINBeauty Health$322.47M0.73$0.06 per share30.52$0.41 per share4.57TLSITriSalus Life Sciences$32.14M6.01N/AN/A($0.83) per share-6.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINOInovio Pharmaceuticals-$107.25M-$3.19N/AN/AN/AN/A-136.93%-89.99%8/6/2025 (Estimated)LNSRLENSAR-$31.40M-$4.85N/A∞N/A-99.17%-737.30%-81.69%8/6/2025 (Estimated)SKINBeauty Health-$29.10M-$0.41N/AN/AN/A-11.94%-67.91%-5.56%8/6/2025 (Estimated)TLSITriSalus Life Sciences-$30.05M-$1.12N/AN/AN/A-84.67%N/A-111.63%8/13/2025 (Estimated)Latest INO, TLSI, SKIN, and LNSR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025TLSITriSalus Life Sciences-$0.20-$0.33-$0.13-$0.39$9.04 million$9.17 million5/13/2025Q1 2025INOInovio Pharmaceuticals-$0.74-$0.51+$0.23-$0.51$0.01 million$0.07 million5/8/2025Q1 2025LNSRLENSAR-$0.1550-$2.32-$2.1650-$2.32$13.40 million$11.53 million5/8/2025Q1 2025SKINBeauty Health-$0.13-$0.08+$0.05-$0.08$63.88 million$69.60 million3/27/2025Q4 2024TLSITriSalus Life Sciences-$0.35-$0.35N/A-$0.40$8.12 million$8.26 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINOInovio PharmaceuticalsN/AN/AN/AN/AN/ALNSRLENSARN/AN/AN/AN/AN/ASKINBeauty HealthN/AN/AN/AN/AN/ATLSITriSalus Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINOInovio PharmaceuticalsN/A2.632.63LNSRLENSARN/A1.811.25SKINBeauty Health12.017.476.43TLSITriSalus Life SciencesN/A2.141.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINOInovio Pharmaceuticals26.79%LNSRLENSAR40.15%SKINBeauty Health93.26%TLSITriSalus Life Sciences2.58%Insider OwnershipCompanyInsider OwnershipINOInovio Pharmaceuticals2.30%LNSRLENSAR66.00%SKINBeauty Health41.00%TLSITriSalus Life Sciences27.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINOInovio Pharmaceuticals32036.67 million35.83 millionOptionableLNSRLENSAR11011.79 million4.01 millionOptionableSKINBeauty Health1,030125.99 million74.34 millionOptionableTLSITriSalus Life Sciences10637.84 million27.43 millionNot OptionableINO, TLSI, SKIN, and LNSR HeadlinesRecent News About These CompaniesTriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion System - Business WireJune 25 at 6:51 AM | businesswire.comTriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital StructureJune 23 at 5:30 PM | businesswire.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Short Interest Down 70.0% in MayJune 13, 2025 | marketbeat.comCantor Fitzgerald Forecasts TLSI FY2026 EarningsJune 10, 2025 | marketbeat.comBank of America Corp DE Raises Holdings in TriSalus Life Sciences, Inc. (NASDAQ:TLSI)June 8, 2025 | marketbeat.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Consensus Recommendation of "Buy" by BrokeragesJune 8, 2025 | marketbeat.comTriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. PatienceMay 30, 2025 | businesswire.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Sees Significant Growth in Short InterestMay 30, 2025 | marketbeat.comRoth Capital Issues Pessimistic Forecast for TLSI EarningsMay 25, 2025 | marketbeat.comJodi Devlin Sells 4,764 Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) StockMay 22, 2025 | insidertrades.comTriSalus outlines at least 50% revenue growth for 2025 as new Medicare code expands addressable marketMay 15, 2025 | msn.comTriSalus Life Sciences, Inc. (TLSI) Q1 2025 Earnings Conference Call TranscriptMay 15, 2025 | seekingalpha.comTriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue EstimatesMay 15, 2025 | zacks.comTriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 GuidanceMay 15, 2025 | businesswire.comTriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference CallMay 12, 2025 | businesswire.comTriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial ResultsApril 30, 2025 | finance.yahoo.comTriSalus Life Sciences, Inc. (TLSI) Soars 6.6%: Is Further Upside Left in the Stock?April 9, 2025 | zacks.comTriSalus Life Sciences, Inc. (TLSI) Soars 6.6%: Is Further Upside Left in the Stock?April 9, 2025 | zacks.comTriSalus Life Sciences: Optimistic Guidance For 2025, But There Are Still RisksMarch 30, 2025 | seekingalpha.comTrisalus outlines 50% revenue growth target for 2025 driven by TriNav expansion and new market penetrationMarch 27, 2025 | msn.comTriSalus Life Sciences’ Q4 Loss Exceeds Projections, Revenue Tops Estimates – Retail Stays PessimisticMarch 27, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINO, TLSI, SKIN, and LNSR Company DescriptionsInovio Pharmaceuticals NASDAQ:INO$2.10 +0.04 (+1.70%) As of 11:41 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.LENSAR NASDAQ:LNSR$12.54 +0.06 (+0.44%) As of 11:42 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.Beauty Health NASDAQ:SKIN$1.88 -0.05 (-2.34%) As of 11:41 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.TriSalus Life Sciences NASDAQ:TLSI$5.11 -0.13 (-2.39%) As of 11:40 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Costco at a Crossroads: Is the Next Move Higher or Lower? AST SpaceMobile's Signal Strengthens as Stock Nears Orbit Oracle Stock Boils Higher, $300 Price Target in Sight 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Which Analyst-Favorite Drone Stock Will Come Out on Top? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
